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A 20:1 combination of cafedrine:theodrenaline (Akrinor®) is widely used in Germany
for the treatment of hypotensive states during anesthesia and in emergency medicine.
Although this drug formulation has been available since 1963, there are few studies
relating to its use and many of the data are only available in German. In this
article, we summarize the available data and propose mechanisms for the effects of
cafedrine/theodrenaline on cardiac muscle cells and vascular smooth muscle cells.
Cafedrine/theodrenaline leads to a rapid increase in mean arterial pressure that is
characterized by increased cardiac preload, stroke volume, and cardiac output. Systemic
vascular resistance and heart rate remain mostly unchanged. Factors which impact the
effects of cafedrine/theodrenaline are gender, high arterial pressure at baseline, use
of β-blockers, and heart failure. Importantly, the drug is frequently used in obstetric
anesthesia without detrimental effects on umbilical cord pH or APGAR score.
Keywords: cafedrine/theodrenaline drug combination, spinal hypotension: treatment, arterial hypotension:
treatment, heart frequency, inotropy, obstetric anesthesia
INTRODUCTION
Hypotension occurs frequently after induction of anesthesia or in emergency medicine. Some
organs are especially susceptible to hypotension (Weyland and Grüne, 2013): the brain, which has
a high oxygen demand and a variable autoregulatory threshold. The kidney and the heart need
adequate perfusion pressure for ultrafiltration (Walsh et al., 2013; Weyland and Grüne, 2013) and
to maintain coronary blood flow (Walsh et al., 2013; Weyland and Grüne, 2013). In hypotensive
patients, timely restoration of blood pressure is important to avoid end-organ damage (Walsh et al.,
2013).
In Germany, a combination of cafedrine (covalently linked norephedrine and theophylline) and
theodrenaline (covalently linked noradrenaline and theophylline) called Akrinor R© is used for the
treatment of hypotension in adults that occurs during emergency situations, general anesthesia,
and regional anesthesia, especially during cesarean sections (Koch and Knoth, 2006). Hypotensive
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states during general anesthesia or following spinal or epidural
anesthesia are the most common situations in which this drug is
administered (Koch and Knoth, 2006). Cafedrine/theodrenaline
has been widely used in Germany since 1963. In 2005,
AWD.pharma GmbH & Co. KG (the company which
owned the rights to the drug at the time) decided to take
cafedrine/theodrenaline off the market because the requirements
for subsequent approval could not be met within the required
timeframe (Radke, 2005; Koch and Wenzel, 2006). However,
because there was no alternative product with comparable
pharmacodynamic characteristics on the German market at that
time, the federal authority granted provisional approval after
consultation with the German Society of Anesthesiology and
Intensive Care (Deutsche Gesellschaft für Anästhesiologie und
Intensivmedizin; DGAI; Koch and Wenzel, 2006; Radke, 2006).
In 2012, cafedrine/theodrenaline received regular approval
by German federal authorities after meeting the approval
requirements (ratiopharm GmbH, 2013).
While hypotensive states in other countries are often treated
with ephedrine and phenylephrine (Lonjaret et al., 2014),
German anesthesiologists often use cafedrine/theodrenaline and
have gained a lot of practical experience with the substance.
86.2% of German hospitals use cafedrine/theodrenaline for the
treatment of hypotension during regional anesthesia for cesarean
section (Marcus et al., 2011).
However, few data relating to its use have been published so
far and the majority of existing publications are only available in
German. Thus, to give the entire scientific community access to
these data, we aim to summarize the current state of knowledge
by providing a comprehensive English-language overview. We
consider this of particular importance for on-going studies in
non-German-speaking countries.
Cafedrine/theodrenaline may have advantages over other
vasopressor drugs. For example, it can be administered via
bolus while catecholamines normally need to be diluted and
administered via syringe pumps. Bolus injection is faster, which
may be beneficial in emergency situations, plus it is more cost
efficient with respect to the disposables.
The combination of cafedrine and theodrenaline is unique
and the substances complement one another. Sole administration
of theodrenaline increases vascular resistance, while cafedrine
exhibits an inotropic effect (Sternitzke et al., 1984). By
administering the two substances in combination the optimal
ratio of cafedrine and theodrenaline can be used. Sakai et al.
tested different ratios in dogs and rats and concluded that 20:1
is the ideal ratio for both a rapid onset and a long-lasting
hypertensive effect (Sakai et al., 1972a).
METHODS
MEDLINE R©, BIOSIS Previews R©, Embase R©, and SciSearch R©
were systematically searched using the following terms: akrinor
OR acrinor OR praxinor OR H-835 OR H835 OR “cafedrine—
theodrenaline” OR (cafedrine AND theodrenaline). The German
and English results were screened manually for relevance.
Reference lists of internal reports provided by the manufacturer
of the drug were screened for additional publications.
PHARMACOKINETICS
The pharmacokinetics of cafedrine/theodrenaline have not
been the subject of extensive research. Theodrenaline’s
pharmacokinetic properties have not been characterized due
to this agent’s lack of stability and the low doses administered.
There are few data available for cafedrine. The initial plasma
level of cafedrine after intravenous administration of 200mg
is 6 µg.ml−1. Cafedrine is metabolized to norephedrine and
several minor metabolites, as summarized by Koch and Knoth
(2006). However, nearly 90% of the administered norephedrine
is excreted via the kidneys, mostly unchanged, within 24 h
(Sinsheimer et al., 1973). Cafedrine has a half-life of 60 min
following both oral and intravenous administration (summarized
in Koch and Knoth, 2006). Data are hard to interpret since it is
not known whether cleavage products are active or even more
active than cafedrine itself; exact metabolites and their potency
are unknown.
EFFECTS ON α- AND β-ADRENERGIC
RECEPTORS
Blood pressure is determined by cardiac output and systemic
vascular resistance. The cardiac effect of cafedrine/theodrenaline
is mediated by β-adrenoceptors, while the resistance of the
blood vessels is largely controlled by α-receptors (Ahlquist,
1967). Possible mechanisms of action of cafedrine/theodrenaline
on cardiac muscle cells and vascular smooth muscle cells are
summarized in Figure 1.
The effects of cafedrine/theodrenaline on cardiac output are
believed to be mediated via β-receptors. Cafedrine/theodrenaline
has a positive inotropic effect in humans, and this can
be abolished by administration of the non-selective β-
adrenoceptor antagonist propranolol (Sternitzke et al., 1976,
1984). In anesthetized patients on β-blocker therapy, onset of
theodrenaline/cafedrine’s effect on blood pressure is delayed and
the effect size is decreased (Heller et al., 2008, 2015).
The effect of cafedrine/theodrenaline on α-receptors is still
under debate (Sakai et al., 1969; Sternitzke et al., 1984; Usichenko
et al., 2006) and may differ with respect to vessel region and
species. In porcine coronary arteries, cafedrine/theodrenaline
induces vasoconstriction only when β-adrenoceptors are
blocked. This vasoconstriction by cafedrine/theodrenaline
can be abolished by the α1-adrenoceptor blocker prazosin
(Usichenko et al., 2006). Theodrenaline alone shows an α-
adrenergic peripheral vasoconstrictor effect in healthy subjects
(Sternitzke et al., 1984). However, this effect is counteracted by
the vasodilatory component of cafedrine, as shown in a study
with healthy subjects (Sternitzke et al., 1984) and dogs (Sakai
et al., 1969). Norephedrine, which is a part of cafedrine, has been
shown to act as a partial agonist at α1-adrenoceptors in rats
(Minneman et al., 1983). Partial agonists can activate receptors.
However, maximum effects are clearly smaller than with the full,
natural agonist. Therefore, partial agonists behave as competitive
antagonists in the presence of the full agonist. At present it is
unclear if norephedrine bound to theophylline shares partial
agonistic activity of norephedrine. Therefore, partial agonistic
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FIGURE 1 | (A) Proposed mechanism of action of cafedrine/theodrenaline in cardiomyocytes: increased inotropy. Cafedrine/theodrenaline is a combination of
norephedrine and theophylline (cafedrine) and noradrenaline and theophylline (theodrenaline). The norephedrine component releases noradrenaline from endogenous
stores (nerve endings). The endogenously released noradrenaline and the noradrenaline component of theodrenaline activate the β1-adrenoceptor (β1-AR) in the heart
muscle cell, which leads—via Gs-proteins—to activation of adenylyl cyclase (AC). Adenylyl cyclase catalyzes the conversion of ATP to cAMP which increases inotropy.
The theophylline component of cafedrine and theodrenaline is expected to inhibit the phosphodiesterases (PDEs) in an unselective manner. PDE3 is the most relevant
PDE in human cardiac tissue. Inhibition of PDE slows degradation of cAMP and increases cAMP concentration, thereby reinforcing the β1-adrenoceptor stimulation.
(B) Proposed mechanism of action of cafedrine/theodrenaline in vascular smooth muscle cells: contradictory effects. The noradrenaline component of theodrenaline
activates the α1-adrenoceptor of the vascular smooth muscle cell. This leads—via Gq-proteins—to activation of phospholipase C (PLC) which ultimately leads to
release of Ca2+ from the endoplasmic reticulum (ER) into the cytosol, thereby initiating muscle contraction. The norephedrine component of cafedrine stimulates the
release of endogenous noradrenaline but may also act as a partial agonist at the α1-adrenoceptor, thereby mediating vasoconstriction by itself but possibly reducing
the effects of endogenous noradrenaline and of the noradrenaline component of theodrenaline. The positive effect on muscle contraction may be counteracted further
by a vasodilatory effect of theophylline, which is thought to inhibit PDE3 and therefore the degradation of cGMP to 5′-GMP. This would result in accumulation of
cGMP. cGMP inhibits release of Ca2+ into the cytosol, leading to relaxation of the muscle, thus counteracting α1-mediated vasoconstriction. The net effect of
α1-mediated vasoconstriction and cGMP-mediated vasodilatation on the vascular muscle cell has not been described yet and may vary depending on the specific
vessel and local distribution of α1-adrenoceptors.
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activity on α1-adrenoceptors by norephedrine could mediate
vasoconstriction by itself but may reduce vasoconstriction
evoked from noradrenaline.
Another expected effect of cafedrine/theodrenaline is
the inhibition of phosphodiesterase (PDE), since both
drugs contain the non-selective PDE inhibitor theophylline
(Sternitzke et al., 1984). PDE degrades second messengers
such as cAMP and cGMP which mediate inotropy and
vascular muscle relaxation, respectively (Maurice et al., 2014).
Because cafedrine/theodrenaline is a 20:1 mixture of the
two drugs, it is believed that the PDE-inhibiting effect of
cafedrine/theodrenaline is primarily mediated by cafedrine.
PDE inhibition is thought to affect both the heart and the
blood vessels (Maurice et al., 2003), even though it has not yet
been proven that cafedrine’s and theodrenaline’s theophylline
component exhibit this effect when administered in combination
with norephedrine (from cafedrine) and noradrenaline (from
theodrenaline). PDE3 inhibition alone can increase inotropy,
independently of catecholamines (Christ et al., 2006; Molenaar
et al., 2013). On the other hand, inhibition of PDE blunts
α1-adrenoceptor-mediated vasoconstriction, as demonstrated
by experiments on internal mammary artery segments (He and
Yang, 1996). It is unclear to what extent PDE inhibition accounts
for the effects of cafedrine/theodrenaline.
In summary we hypothesize that cafedrine/theodrenaline
acts predominantly via β-adrenoceptors in the heart, directly
activating β1-adrenoceptors, and probably reinforcing the
effects of β1-adrenoceptor stimulation via PDE inhibition.
Effects on isolated vessels are difficult to predict due to the
different pharmacodynamics of the individual constitutes of
cafedrine/theodrenaline.
INDIVIDUAL EFFECTS OF CAFEDRINE
AND THEODRENALINE
If theodrenaline is intravenously administered as a single drug
to healthy subjects, this leads to an immediate, rapid increase in
mean arterial blood pressure (MAP) by 28%; this effect decreases
gradually up to 20 min after administration (Sternitzke et al.,
1984).
On the other hand, if cafedrine is intravenously administered
as a single drug to healthy subjects without arterial hypotension,
the increase in blood pressure is delayed, but lasts longer
(Sternitzke et al., 1984). The maximum effect of 200mg cafedrine
was noted after 20 min (Sternitzke et al., 1984). However, one
in vitro study suggests that the pressor effect of cafedrine may
exhibit tachyphylaxis (Daweke and Oberdorf, 1958), while an
animal study showed that repeated oral administration is not
associated with a reduction in the pressor effect of this agent
(Sakai et al., 1972b).
EFFECTS OF CAFEDRINE AND
THEODRENALINE IN COMBINATION
Cardiovascular Effects
A number of animal and clinical studies have been published
on the cardiovascular effects on cafedrine/theodrenaline. These
studies involve different patient populations, different designs,
and different measured outcomes. We give an overview of the
relevant study details in Supplemental Table 1 (Supplemental
Digital Content).
Administration of both drugs to healthy subjects leads to an
increase in cardiac preload, stroke volume, and cardiac output
(Fischer and Weis, 1965; Schieffer et al., 1971; Sternitzke et al.,
1984; Muller et al., 1985). Cafedrine/theodrenaline has a positive
inotropic effect (Fischer and Weis, 1965; Schieffer et al., 1971;
Sternitzke et al., 1975, 1984; Muller et al., 1985) and the heart
rate in awake patients is mildly decreased (Fischer and Weis,
1965; Sternitzke et al., 1976). Conversely, a more recent study
reported an increase in heart rate in patients under anesthesia
after cafedrine/theodrenaline administration (Heller et al., 2008).
Cafedrine/theodrenaline shows a mostly unchanged systemic
vascular resistance in healthy subjects. (Fischer and Weis, 1965;
Sternitzke et al., 1984).
Theodrenaline leads to a rapid, peripheral vasoconstriction
mediated via α-adrenoceptors. This may be due to the
noradrenaline component of theodrenaline (Sternitzke et al.,
1984). This effect may be in competition to the partial
agonistic activity of cafedrine’s norephedrine component on α-
receptors: Norephedrine may act as a partial agonist at the
α1-adrenoceptor (Minneman et al., 1983), thereby mediating
vasoconstriction by itself but possibly reducing the effects of
endogenous noradrenaline and of the noradrenaline component
of theodrenaline.
Animal data show an increased coronary blood flow
after cafedrine/theodrenaline administration, which provides an
increased amount of oxygen (Hahn et al., 1985). Together with
the moderate decrease in heart rate, this may compensate for
the increased oxygen consumption which results from increased
inotropy (Hahn et al., 1985; Koch and Knoth, 2006). Studies
involving anesthetized dogs in cardiogenic shock showed a
40% increase in oxygen consumption after administration of
cafedrine/theodrenaline, but also an increase in blood flow
by 181% (Hahn et al., 1985). Another study involving nine
healthy anesthetized dogs showed similar results (Schlepper and
Witzleb, 1962). The authors of these studies concluded that
cafedrine/theodrenaline may provide a sufficient oxygen supply
due to this compensation (Schlepper and Witzleb, 1962; Hahn
et al., 1985; Heller et al., 2008). This might be one explanation
for the positive profile of cafedrine/theodrenaline in patients
with myocardial infarction (Heller and Grosser, 1974; Koch and
Knoth, 2006; Heller et al., 2008). It should be noted that in
patients with myocardial injury and hypotension, the increase
in blood pressure is substantially larger than in healthy subjects
(18 mmHg vs. 49 mmHg after intramuscular administration;
Schleusing and Bartsch, 1963).
Patients Undergoing General or Regional
Anesthesia
The effects of cafedrine/theodrenaline were investigated in
a retrospective analysis of pooled data from 297 patients
who underwent regional or general anesthesia (Heller
et al., 2008). Patients received 53 ± 30/2.65 ± 1.5mg
cafedrine/theodrenaline.kg−1 when the systolic blood pressure
dropped below 80% of the baseline value. A rapid increase
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in blood pressure (maximum mean arterial pressure (MAP)
increase 9 ± 4 min after drug administration) was observed.
The increase in MAP after 5 min was 11 ± 14 mmHg and after
10 min 14 ± 16 mmHg. The ED50 of cafedrine/theodrenaline
was 1.49/0.075 mg.kg−1 to achieve a 10% increase in MAP
after 5 min, and 0.53/0.027 mg.kg−1 to achieve a 10% increase
after 10 min. Analysis of data from different dose groups in
the range from 0.31 ± 0.07 mg/kg to 1.25 ± 0.44 suggested a
direct dose-response. Cafedrine/theodrenaline’s effect on mean
arterial pressure was significantly less substantial in patients
with heart failure and in patients with a higher MAP at baseline.
Furthermore, male patients showed a less substantial effect than
females. The authors suggested that a higher intravascular fluid
volume in women might explain this difference (Heller et al.,
2008).
The effects described above are supported by the results
of a more recent study which demonstrated an increase in
MAP of 11 ± 16 mmHg 5 min after administration of 1.25 ±
1.0 mg/64 ± 50 µg cafedrine/theodrenaline.kg−1 in a separate
patient population undergoing regional and general anesthesia.
Patients were included after a drop in MAP ≥ 5% (Heller et al.,
2015). The highest MAP was reached 17.4 ± 9.0 min after
administration of an average dose of 1.27 ± 1.0 mg/64 ± 50
µg cafedrine/theodrenaline.kg−1. The same authors confirmed a
more rapid 10% MAP increase in women and a faster increase
to maximum MAP in patients without heart failure. Patients
without heart failure also required less cafedrine/theodrenaline
to reach a similar magnitude of MAP increase: 1.16 ± 0.77
mg/58.0 ± 38.5 µg cafedrine/theodrenaline.kg−1 to achieve an
increase of 14 ± 14 mmHg vs. 1.78 ± 1.67 mg/89.0 ± 83.5 µg
cafedrine/theodrenaline.kg−1 to achieve an increase of 14 ± 16
mmHg.
In a study involving 20 patients undergoing epidural
anesthesia, Seitz et al. showed that MAP increased by 43.0% after
administration of 100/5mg cafedrine/theodrenaline (Seitz et al.,
1985).
Shock
Animal data have demonstrated that cafedrine/theodrenaline
causes positive inotropy in dogs with cardiogenic shock,
including an increase in MAP, heart rate, pressure in the left
ventricle, and blood flow in A. femoralis and R. circumflexus
(Hahn et al., 1985). Two older (German) publications
recommend the use of cafedrine/theodrenaline in patients
with non-hemorrhagic shock (Böhmert, 1969; Bartels et al.,
1978), one of which specifies that cafedrine/theodrenaline leads
to a stronger increase of systolic blood pressure compared to the
diastolic pressure in normovolaemic patients and therefore to a
larger amplitude. The increased blood pressure is mainly due to
an increased stroke volume. The previously-increased systemic
vascular resistance decreased after cafedrine/theodrenaline
administration (Böhmert, 1969).
Safety Profile
When cafedrine/theodrenaline was launched in Germany in the
1960s, safety standards for medicinal products were very different
from today.
Cafedrine/theodrenaline are theophylline-derivates. There
are studies showing that theophylline may lead to tachycardia
and arrhythmias (Bittar and Friedman, 1991; Chazan et al.,
1995). In the course of developing cafedrine/theodrenaline, a
number of theophylline-derivates were searched for candidates
that combine the beneficial cardiovascular effect and a better
side effect profile. The derivates’ circulatory effects indeed
differ from theophylline (Daweke and Oberdorf, 1958;
Schlepper and Witzleb, 1962). In general, the impact of
cafedrine/theodrenaline differs from those of the individual
substances (Sternitzke et al., 1984). A review from 2006 states
that tachycardia and arrhythmias are hardly ever observed with
cafedrine/theodrenaline (Koch and Wenzel, 2006).
After more than 50 years of use and∼50–100 million patients
treated with the drug, cafedrine/theodrenaline has an anecdotally
good safety record (ratiopharm GmbH, 2013), but there are few
safety data from clinical studies.
Renal Function
While theodrenaline alone showed an antidiuretic effect in rats,
cafedrine and a 20:1 combination of cafedrine and theodrenaline
exhibited diuretic effects (Sakai et al., 1972a). The authors
of a small study involving 12 patients (normotensive or
hypotensive, normal, or impaired kidney function) concluded
that cafedrine/theodrenaline shows a favorable renal profile.
Based on theoretical considerations, they concluded that its
renal profile is especially favorable compared with vasopressor
sympathomimetics (Bihler et al., 1972). A small increase in both
glomerular filtration rate and renal blood flow occurred in their
study, but both were non-significant (Bihler et al., 1972).
Obstetrics
Cafedrine/theodrenaline is regularly used in obstetric anesthesia
(Marcus et al., 2011). Pregnant women are at a particular risk
of hypotension during anesthesia (general and regional) due to
reduced cardiovascular reserve (Koch and Knoth, 2006), but
preservation of uteroplacental perfusion is important in order to
avoid fetal acidosis (Koch and Knoth, 2006).
Experiments in pregnant sheep without hypotension
demonstrated an increase in maternal MAP of maximum 14.2 ±
3.2% for 6 min after administration of a fixed dose of 100/5mg
cafedrine/theodrenaline (Gogarten et al., 2004). The authors
of this animal study highlight possible differences between
species and suggest very careful dosing to avoid a decrease in
uteroplacental perfusion.
In one retrospective study involving parturients undergoing
spinal anesthesia for cesarean section, 117 out of 173 (68%)
patients exhibited a drop in blood pressure. Fifty-six patients
whose systolic blood pressure remained within defined limits,
i.e., ≥120 mmHg or >80% of baseline blood pressure, were
assigned to the non-treatment group and were compared with
the hypotensive patients treated with cafedrine/theodrenaline
(Clemens et al., 2010). In the treated group, an increase in mean
systolic blood pressure of 8.6 mmHg 1 min after administration
of a mean of 43 ± 11/2.2 ± 0.6mg cafedrine/theodrenaline was
observed. Comparably, systolic blood pressure increased (mean
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21.3 mmHg) and no negative impact on umbilical cord pH or
APGAR score was observed.
The German Society of Anesthesiology and Intensive Care
Medicine and the German Association of Gynecology and
Obstetrics recommend the use of cafedrine/theodrenaline, as an
alternative to phenylephrine, in hypotensive states associated
with anesthesia for Cesarean section (Durchführung von
Analgesie- und Anästhesieverfahren in der Geburtshilfe, 2009).
However, this recommendation is not based on randomized
clinical studies.
Alternative Routes of Administration
A study by Schleusing and Bartsch compared intravenous
and intramuscular administration of 200/10mg
cafedrine/theodrenaline in 25 healthy volunteers and 26
patients with cardiovascular disease. When compared with the
intravenous route, intramuscular administration induced a more
moderate and delayed, but also a longer lasting increase in blood
pressure (Schleusing and Bartsch, 1963). This difference between
intramuscular and intravenous administration was confirmed
in a study involving 252 patients with intra- or post-operative
hypotension (Eichler and Stephan, 1964).
Measurement of cardiovascular parameters before and 30 min
after oral administration of 100/5mg cafedrine/theodrenaline
and measurement of orthostatic cardiovascular changes after
4 weeks of daily oral cafedrine/theodrenaline administration
were conducted in a study involving 20 children with
orthostatic hypotension (Hoffmann and Sternitzke, 1977). Use of
cafedrine/theodrenaline resulted in constriction of the leg veins
and, as a result, a 37% reduction in venous pooling (Hoffmann
and Sternitzke, 1977). In combination with increased venous
return and increased contractility, this led to increased cardiac
output and decreased systemic vascular resistance (Hoffmann
and Sternitzke, 1977).
ASSESSMENT OF DATA QUALITY
Many of the data cited in this review were published in the 1960s
and scientific standards have changed substantially since then.
However, data relating to the use of cafedrine/theodrenaline in
the management of hypotension treatment are scarce, and these
studies have been included to give a comprehensive summary of
the current state of knowledge.
FUTURE RESEARCH
Future areas of research on cafedrine/theodrenaline could
include: (a) a more comprehensive description of the
pharmacokinetics (e.g., determination of how long the
individual components stay in the body); (b) further
elucidation of the mechanism of action of each of the
components and their cleavage products; (c) characterization
of the inotropic, bathmotropic, and chronotropic effects of
cafedrine/theodrenaline (possibly involving the use of isolated
Langendorff preparations); (d) characterization of the temporal
relationship between cafedrine/theodrenaline administration
and vasoconstriction or vasodilatation in isolated venous
and arterial vessel preparations; and (e) comparison of the
effects of cafedrine/theodrenaline and alternative drugs on
blood pressure, heart rate, and cardiac output in a clinical
context (e.g., head-to-head comparisons with internationally
used substances, such as ephedrine and phenylephrine). A
multicenter, non-interventional study of cafedrine/theodrenaline
vs. ephedrine for the treatment of perioperative hypotensive
states is currently ongoing, and is registered in ClinicalTrials.gov
(NCT02893241) and in the German Clinical Trials Register
(DRKS-ID: DRKS00010740).
CAFEDRINE/THEODRENALINE IN
COMPARISON WITH OTHER PRESSOR
AGENTS
In this review article we focus on cafedrine/theodrenaline, but
there are other antihypotensive agents available. Phenylephrine
stimulates predominantly the α-receptors and is a strong
vasopressor which leads to an increase in blood pressure and a
reflex bradycardia. The vascular resistance is increased, which in
turn leads to a decrease of the cardiac output (Sintetica, 2015).
Ephedrine stimulates both, α- and β-receptors, has an inotropic
and chronotropic effect and therefore increases the cardiac
output (Sintetica, 2014). In addition, ephedrine stimulates the
heart rate (Loubert, 2012).
Unfortunately, there is a lack of high quality head-to-
head studies between cafedrine/theodrenaline and other
pressor agents. However, one study from 1985 compared
equipotent doses of cafedrine/theodrenaline, etilefrine,
ephedrine, norfenefrin, and amezinium in 50 anesthetized
patients (Muller et al., 1985). The authors concluded that
vasopressors that stimulate predominantly the α-receptors, such
as norfenefrin, may lead to an unwanted high increase of the
systemic vascular resistance and a subsequent decrease of cardiac
output. Predominantly betamimetic substances may display a
delayed increase of blood pressure. The authors recommended
the use of α- and β-receptor-stimulating substances, such as
ephedrine and cafedrine/theodrenaline, which successively
provide both venoconstriction and cardiac stimulation.
CONCLUSION AND AUTHORS’ PERSONAL
OPINION
Cafedrine/theodrenaline leads to a rapid increase in blood
pressure and the pharmacologic properties exhibit many of
the characteristics of an ideal antihypotensive agent. As
outlined in section “Effects of Cafedrine and Theodrenaline
in Combination,” the increase in blood pressure is mainly
due to increased inotropy, cardiac preload, stroke volume, and
cardiac output, while the systemic vascular resistance remains
largely unchanged. This is an advantage compared to drugs
which act predominantly via activation of α1-adrenoceptors. In
addition, the heart rate remains mostly unchanged. This may be
advantageous compared with drugs that exhibit a pronounced
activation of β1-receptors, since tachycardia is an unwanted
side effect with respect to myocardial oxygen consumption. The
duration of the effect is long-lasting possibly due to the proposed
combination of direct and indirect sympathomimetic properties
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and simultaneous PDE-inhibition (Figure 1). The long-lasting
effect enables comfortable drug handling, because repeated bolus
administrations or the use of syringe pumps can be avoided.
Also, this drug combination has a very good safety record, as
it has been used widely in Germany since the 1960s. However,
it should be noted that there are only few safety data from
controlled trials available.
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